Regional lymphadenectomy In patients with microscopic melanoma in regional lymph nodes, immediate completion lymphadenectomy has widely been replaced by active observation, as long as close follow-up with nodal ultrasound surveillance can be achieved
The clinical trials and FDA guidelines vary between these medications
What users commonly report: Still very little that's visible
Safety Considerations and Reporting Suspected Side Effects The most common adverse effects are gastrointestinal, including nausea, vomiting, and diarrhoea, particularly during dose escalation
Also known as: 1401708-83-5, L-isoleucinamide, n-(1-oxohexyl)-l-tyrosyl-n-(6-amino-6-oxohexyl)-, 9wyx65a5c2, N-hexanoic-tyr-ile-(6) aminohexanoic amide, Pnb-0408, 6-(2-(2-hexanamido-3-(4-hydroxyphenyl)propanamido)-3-methylpentanamido)hexanamide Molecular Formula C 27 H 44 N 4 O 5 Molecular Weight 504.7 g/mol InChI Key XEUVNVNAVKZSPT-JTJYXVOQSA-N 1 2D Structure 2 Identification 2.1 Computed Descriptors 2.1.1 IUPAC Name (2S,3S)-N-(6-amino-6-oxohexyl)-2-[[(2S)-2-(hexanoylamino)-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanamide 2.1.2 InChI InChI=1S/C27H44N4O5/c1-4-6-8-12-24(34)30-22(18-20-13-15-21(32)16-14-20)26(35)31-25(19(3)5-2)27(36)29-17-10-7-9-11-23(28)33/h13-16,19,22,25,32H,4-12,17-18H2,1-3H3,(H2,28,33)(H,29,36)(H,30,34)(H,31,35)/t19-,22-,25-/m0/s1 2.1.3 InChI Key XEUVNVNAVKZSPT-JTJYXVOQSA-N 2.1.4 Canonical SMILES CCCCCC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C(C)CC)C(=O)NCCCCCC(=O)N 2.1.5 Isomeric SMILES CCCCCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCCCCCC(=O)N 2.2 Other Identifiers 2.2.1 UNII 2.3 Synonyms 2.3.1 MeSH Synonyms 1
